Clinical Trials for Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects some people who have psoriasis. It can cause joint pain, swelling, and stiffness, as well as effects on tendons, ligaments, and the spine. Treating PsA often requires biologics or targeted small molecules, which are expensive and frequently subject to insurance prior authorization and denial.
Clinical trials for psoriatic arthritis are actively developing new treatment options, including treatments that work for people who have not responded to existing biologics.
The National Psoriasis Foundation estimates that approximately 1 in 3 people with psoriasis will develop psoriatic arthritis, affecting more than 1 million Americans.
What Types of Trials Are Available?
IL-17 inhibitor trials study secukinumab (Cosentyx), ixekizumab (Taltz), and next-generation agents in this class. IL-17 inhibitors are among the most effective treatments for PsA affecting both joints and skin. IL-23 inhibitor trials build on the success of agents like ustekinumab (Stelara) with newer, more selective antibodies targeting the IL-23 pathway. JAK inhibitor trials study oral options like tofacitinib and upadacitinib, which may benefit people who have not responded to injectable biologics. Combination and treat-to-target trials study whether achieving clearly defined disease targets (minimal disease activity) leads to better long-term outcomes.Search ClinicalTrials.gov for currently recruiting trials.
Am I Eligible?
Common eligibility factors for PsA trials include:
- Confirmed psoriatic arthritis diagnosis
- Active joint involvement (minimum tender and swollen joint counts)
- Prior treatment history with conventional DMARDs (like methotrexate) or biologics
- Current skin psoriasis involvement (some trials require active plaque psoriasis as well)
- No current serious infections or other contraindicated conditions
Some trials specifically enroll biologic-naive participants. Others require prior biologic exposure. The range of options is broad.
Talk to your rheumatologist or dermatologist to evaluate your specific profile. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
Biologics for psoriatic arthritis are frequently denied due to step therapy requirements, which often force you to try older medications before insurers will approve newer, more targeted options. If your rheumatologist has recommended a biologic and your insurer has denied it, you have the right to appeal.
While your appeal is in progress, clinical trials studying similar or newer mechanisms may offer access to treatment. Many people find that their specific treatment history -- including a prior denial -- actually aligns well with the eligibility profile of certain trials.
Read more: Denied Humira -- clinical trial options | Denied Stelara -- clinical trial options
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for psoriatic arthritis free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find psoriatic arthritis trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Stelara or Cosentyx?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Stelara or Cosentyx or similar medications.